Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Ejhaem|July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease RegistryDaniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
Ejhaem|December 18, 2024
Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG reportJasmine Naru, Megan Othus, ChenWei Lin, et al.
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
Leukemia|January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsJacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Ejhaem|July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease RegistryDaniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
Ejhaem|December 18, 2024
Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG reportJasmine Naru, Megan Othus, ChenWei Lin, et al.
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2023
The New NCI Precision Medicine TrialsLyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
Leukemia|January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsJacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
Pageof 17